Cardiomyocyte specific ablation of p53 is not sufficient to block doxorubicin induced cardiac fibrosis and associated cytoskeletal changes

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Feridooni, Tiam ^a   Hotchkiss, Adam ^a   Remley Carr, Sarah ^a   Saga, Yumiko ^b   Pasumarthi, Kishore B S ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b NATIONAL INSTITUTE OF GENETICS   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TUBULIN; DOXORUBICIN; PROTEIN P53; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; ANTINEOPLASTIC ANTIBIOTIC; BIOLOGICAL MARKER; CRE RECOMBINASE; INTEGRASE; SUPEROXIDE; TUBULIN;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; CYTOSKELETON; DISEASE COURSE; DRUG EFFECT; DRUG RESPONSE; GENE INACTIVATION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; MALE; MOUSE; NONHUMAN; PROTEIN DEPLETION; SINGLE DRUG DOSE; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; CYTOLOGY; FIBROSIS; FLUORESCENT ANTIBODY TECHNIQUE; HEART DISEASE; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; WESTERN BLOTTING;

MUS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CELL PROLIFERATION; CYTOSKELETON; DOXORUBICIN; FIBROSIS; FLUORESCENT ANTIBODY TECHNIQUE; HEART DISEASES; INTEGRASES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCYTES, CARDIAC; REACTIVE OXYGEN SPECIES; SUPEROXIDES; TUBULIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79960858307     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022801     Document Type: Article

References (69)

1. Ludke AR, Al-Shudiefat AA, Dhingra S, Jassal DS, Singal PK, (2009) A concise description of cardioprotective strategies in doxorubicin-induced cardiotoxicity. Can J Physiol Pharmacol 87: 756-763.
2. Takemura G, Fujiwara H, (2007) Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 49: 330-352.
3. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L, (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56: 185-229.
4. Binaschi M, Farinosi R, Borgnetto ME, Capranico G, (2000) In vivo site specificity and human isoenzyme selectivity of two topoisomerase II-poisoning anthracyclines. Cancer Res 60: 3770-3776.
5. Binaschi M, Bigioni M, Cipollone A, Rossi C, Goso C, et al. (2001) Anthracyclines: selected new developments. Curr Med Chem Anticancer Agents 1: 113-130.
6. Fajardo G, Bernstein D, (2007) Endocannabinoid inhibition: a new cardioprotective strategy against doxorubicin cardiotoxicity. J Am Coll Cardiol 50: 537-539.
7. Mukhopadhyay P, Rajesh M, Batkai S, Kashiwaya Y, Hasko G, et al. (2009) Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am J Physiol Heart Circ Physiol 296: H1466-1483.
8. Nithipongvanitch R, Ittarat W, Cole MP, Tangpong J, Clair DK, et al. (2007) Mitochondrial and nuclear p53 localization in cardiomyocytes: redox modulation by doxorubicin (Adriamycin)? Antioxid Redox Signal 9: 1001-1008.
9. Kalyanaraman B, Joseph J, Kalivendi S, Wang S, Konorev E, et al. (2002) Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol Cell Biochem 234-235: 119-124.
10. Chelikani P, Fita I, Loewen PC, (2004) Diversity of structures and properties among catalases. Cell Mol Life Sci 61: 192-208.
11. Green PS, Leeuwenburgh C, (2002) Mitochondrial dysfunction is an early indicator of doxorubicin-induced apoptosis. Biochim Biophys Acta 1588: 94-101.
12. Clementi ME, Giardina B, Di Stasio E, Mordente A, Misiti F, (2003) Doxorubicin-derived metabolites induce release of cytochrome C and inhibition of respiration on cardiac isolated mitochondria. Anticancer Res 23: 2445-2450.
13. Nithipongvanitch R, Ittarat W, Velez JM, Zhao R, St Clair DK, et al. (2007) Evidence for p53 as guardian of the cardiomyocyte mitochondrial genome following acute adriamycin treatment. J Histochem Cytochem 55: 629-639.
14. Pointon AV, Walker TM, Phillips KM, Luo J, Riley J, et al. (2010) Doxorubicin in vivo rapidly alters expression and translation of myocardial electron transport chain genes, leads to ATP loss and caspase 3 activation. PLoS One 5: e12733.
15. Yen HC, Oberley TD, Vichitbandha S, Ho YS, St Clair DK, (1996) The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J Clin Invest 98: 1253-1260.
16. Pouillart P, (2004) Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines. Cancer Treat Rev 30: 643-650.
17. Todorova VK, Kaufmann Y, Hennings LJ, Klimberg VS, (2010) Glutamine regulation of doxorubicin accumulation in hearts versus tumors in experimental rats. Cancer Chemother Pharmacol 66: 315-323.
18. Mukhopadhyay P, Batkai S, Rajesh M, Czifra N, Harvey-White J, et al. (2007) Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol 50: 528-536.
19. Li L, Takemura G, Li Y, Miyata S, Esaki M, et al. (2006) Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. Circulation 113: 535-543.
20. Li L, Takemura G, Li Y, Miyata S, Esaki M, et al. (2007) Granulocyte colony-stimulating factor improves left ventricular function of doxorubicin-induced cardiomyopathy. Lab Invest 87: 440-455.
21. Shizukuda Y, Matoba S, Mian OY, Nguyen T, Hwang PM, (2005) Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice. Mol Cell Biochem 273: 25-32.
22. Liu X, Chua CC, Gao J, Chen Z, Landy CL, et al. (2004) Pifithrin-alpha protects against doxorubicin-induced apoptosis and acute cardiotoxicity in mice. Am J Physiol Heart Circ Physiol 286: H933-939.
23. Zhu W, Soonpaa MH, Chen H, Shen W, Payne RM, et al. (2009) Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation 119: 99-106.
24. Klappacher G, Franzen P, Haab D, Mehrabi M, Binder M, et al. (1995) Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol 75: 913-918.
25. Shirani J, Pick R, Roberts WC, Maron BJ, (2000) Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol 35: 36-44.
26. Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE, (2005) Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 131: 561-578.
27. Saga Y, Miyagawa-Tomita S, Takagi A, Kitajima S, Miyazaki J, et al. (1999) MesP1 is expressed in the heart precursor cells and required for the formation of a single heart tube. Development 126: 3437-3447.
28. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, et al. (2001) Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 29: 418-425.
29. Gaspard GJ, Pasumarthi KB, (2008) Quantification of cardiac fibrosis by colour-subtractive computer-assisted image analysis. Clin Exp Pharmacol Physiol 35: 679-686.
30. Sun Q, Zhang F, Wafa K, Baptist T, Pasumarthi KB, (2009) A splice variant of cyclin D2 regulates cardiomyocyte cell cycle through a novel protein aggregation pathway. J Cell Sci 122: 1563-1573.
31. Pasumarthi KB, Nakajima H, Nakajima HO, Soonpaa MH, Field LJ, (2005) Targeted expression of cyclin D2 results in cardiomyocyte DNA synthesis and infarct regression in transgenic mice. Circ Res 96: 110-118.
32. Miller FJ Jr, Gutterman DD, Rios CD, Heistad DD, Davidson BL, (1998) Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. Circ Res 82: 1298-1305.
33. Kim KK, Soonpaa MH, Daud AI, Koh GY, Kim JS, et al. (1994) Tumor suppressor gene expression during normal and pathologic myocardial growth. J Biol Chem 269: 22607-22613.
34. Eghbali M, Weber KT, (1990) Collagen and the myocardium: fibrillar structure, biosynthesis and degradation in relation to hypertrophy and its regression. Mol Cell Biochem 96: 1-14.
35. Brown RD, Ambler SK, Mitchell MD, Long CS, (2005) The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol 45: 657-687.
36. Dudnakova TV, Lakomkin VL, Tsyplenkova VG, Shekhonin BV, Shirinsky VP, et al. (2003) Alterations in myocardial cytoskeletal and regulatory protein expression following a single Doxorubicin injection. J Cardiovasc Pharmacol 41: 788-794.
37. Rabkin SW, Sunga P, (1987) The effect of doxorubicin (adriamycin) on cytoplasmic microtubule system in cardiac cells. J Mol Cell Cardiol 19: 1073-1083.
38. Simunek T, Sterba M, Popelova O, Adamcova M, Hrdina R, et al. (2009) Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 61: 154-171.
39. Dunkern TR, Wedemeyer I, Baumgartner M, Fritz G, Kaina B, (2003) Resistance of p53 knockout cells to doxorubicin is related to reduced formation of DNA strand breaks rather than impaired apoptotic signaling. DNA Repair (Amst) 2: 49-60.
40. Chaiswing L, Cole MP, Ittarat W, Szweda LI, St Clair DK, et al. (2005) Manganese superoxide dismutase and inducible nitric oxide synthase modify early oxidative events in acute adriamycin-induced mitochondrial toxicity. Mol Cancer Ther 4: 1056-1064.
41. Primeau AJ, Rendon A, Hedley D, Lilge L, Tannock IF, (2005) The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res 11: 8782-8788.
42. Song H, Conte JV Jr, Foster AH, McLaughlin JS, Wei C, (1999) Increased p53 protein expression in human failing myocardium. J Heart Lung Transplant 18: 744-749.
43. Yoshida M, Shiojima I, Ikeda H, Komuro I, (2009) Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA damage-ATM-p53-apoptosis pathway and attenuated by pitavastatin through the inhibition of Rac1 activity. J Mol Cell Cardiol 47: 698-705.
44. Mailloux A, Grenet K, Bruneel A, Beneteau-Burnat B, Vaubourdolle M, et al. (2001) Anticancer drugs induce necrosis of human endothelial cells involving both oncosis and apoptosis. Eur J Cell Biol 80: 442-449.
45. Lorenzo E, Ruiz-Ruiz C, Quesada AJ, Hernandez G, Rodriguez A, et al. (2002) Doxorubicin induces apoptosis and CD95 gene expression in human primary endothelial cells through a p53-dependent mechanism. J Biol Chem 277: 10883-10892.
46. Spiel AO, Gilbert JC, Jilma B, (2008) von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation 117: 1449-1459.
47. Bouska A, Eischen CM, (2009) Murine double minute 2: p53-independent roads lead to genome instability or death. Trends Biochem Sci 34: 279-286.
48. Strasser A, Harris AW, Jacks T, Cory S, (1994) DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 79: 329-339.
49. Tsang WP, Chau SP, Kong SK, Fung KP, Kwok TT, (2003) Reactive oxygen species mediate doxorubicin induced p53-independent apoptosis. Life Sci 73: 2047-2058.
50. Lim CC, Zuppinger C, Guo X, Kuster GM, Helmes M, et al. (2004) Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J Biol Chem 279: 8290-8299.
51. Popowich DA, Vavra AK, Walsh CP, Bhikhapurwala HA, Rossi NB, et al. (2010) Regulation of reactive oxygen species by p53: implications for nitric oxide-mediated apoptosis. Am J Physiol Heart Circ Physiol 298: H2192-2200.
52. Ambs S, Ogunfusika MO, Merriam WG, Bennett WP, Billiar TR, et al. (1998) Up-regulation of inducible nitric oxide synthase expression in cancer-prone p53 knockout mice. Proc Natl Acad Sci U S A 95: 8823-8828.
53. Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE, et al. (2005) The antioxidant function of the p53 tumor suppressor. Nat Med 11: 1306-1313.
54. Shacka JJ, Sahawneh MA, Gonzalez JD, Ye YZ, D'Alessandro TL, et al. (2006) Two distinct signaling pathways regulate peroxynitrite-induced apoptosis in PC12 cells. Cell Death Differ 13: 1506-1514.
55. Caulfield JB, Bittner V, (1988) Cardiac matrix alterations induced by adriamycin. Am J Pathol 133: 298-305.
56. Sanchez-Quintana D, Climent V, Garcia-Martinez V, Macias D, Hurle JM, (1994) Extracellular matrix arrangement in the papillary muscles of the adult rat heart. Alterations after doxorubicin administration and experimental hypertension. Basic Res Cardiol 89: 279-292.
57. Konishi M, Haraguchi G, Ohigashi H, Ishihara T, Saito K, et al. (2011) Adiponectin protects against doxorubicin-induced cardiomyopathy by anti-apoptotic effects through AMPK up-regulation. Cardiovasc Res 89: 309-319.
58. Mukhopadhyay P, Rajesh M, Batkai S, Patel V, Kashiwaya Y, et al. (2010) CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. Cardiovasc Res 85: 773-784.
59. Goetzenich A, Hatam N, Zernecke A, Weber C, Czarnotta T, et al. (2009) Alteration of matrix metalloproteinases in selective left ventricular adriamycin-induced cardiomyopathy in the pig. J Heart Lung Transplant 28: 1087-1093.
60. Spallarossa P, Altieri P, Garibaldi S, Ghigliotti G, Barisione C, et al. (2006) Matrix metalloproteinase-2 and-9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase. Cardiovasc Res 69: 736-745.
61. Bai P, Mabley JG, Liaudet L, Virag L, Szabo C, et al. (2004) Matrix metalloproteinase activation is an early event in doxorubicin-induced cardiotoxicity. Oncol Rep 11: 505-508.
62. Picard F, Brehm M, Fassbach M, Pelzer B, Scheuring S, et al. (2006) Increased cardiac mRNA expression of matrix metalloproteinase-1 (MMP-1) and its inhibitor (TIMP-1) in DCM patients. Clin Res Cardiol 95: 261-269.
63. Giannakakou P, Sackett DL, Ward Y, Webster KR, Blagosklonny MV, et al. (2000) p53 is associated with cellular microtubules and is transported to the nucleus by dynein. Nat Cell Biol 2: 709-717.
64. Murphy M, Hinman A, Levine AJ, (1996) Wild-type p53 negatively regulates the expression of a microtubule-associated protein. Genes Dev 10: 2971-2980.
65. Nguyen HL, Gruber D, Bulinski JC, (1999) Microtubule-associated protein 4 (MAP4) regulates assembly, protomer-polymer partitioning and synthesis of tubulin in cultured cells. J Cell Sci 112 (Pt 12): 1813-1824.
66. Cleveland DW, Lopata MA, Sherline P, Kirschner MW, (1981) Unpolymerized tubulin modulates the level of tubulin mRNAs. Cell 25: 537-546.
67. Sato H, Nagai T, Kuppuswamy D, Narishige T, Koide M, et al. (1997) Microtubule stabilization in pressure overload cardiac hypertrophy. J Cell Biol 139: 963-973.
68. Takahashi M, Shiraishi H, Ishibashi Y, Blade KL, McDermott PJ, et al. (2003) Phenotypic consequences of beta1-tubulin expression and MAP4 decoration of microtubules in adult cardiocytes. Am J Physiol Heart Circ Physiol 285: H2072-2083.
69. Cooper Gt, (2006) Cytoskeletal networks and the regulation of cardiac contractility: microtubules, hypertrophy, and cardiac dysfunction. Am J Physiol Heart Circ Physiol 291: H1003-1014.